Fig 1: Identification of transferrin receptor as molecular target of aptamer HG1-9. (A) Flow cytometry analysis of HG1-9 binding to Jurkat cells pretreated by different concentrations of trypsin or proteinase K. (B) Flow cytometry analysis of HeLa and Jurkat cells dual-stained by aptamer HG1-9 (labeled by Cy5) and antibody anti-TfR (labeled by PE). The cross-quadrant gate in each bivariate histogram was respectively set according to negative control in different cell lines. (C) Confocal imaging of HeLa cells dual-stained by aptamer HG1-9 (labeled by FITC, 200 nM) and anti-TfR antibody (labeled by PE-second antibody, dilution of 1:20), the scale is 10 μm. (D) Relative median fluorescence intensities of aptamer HG1-9 and anti-TfR antibody binding to HeLa cells after siRNA knockdown. Relative median fluorescence intensities were acquired according to formula of F = (F1 − F0)/F0. Blank bars represent cells without any treatment, grey bars represent cells treated by si-NC sequence, and white bars represent cells treated by si-TfR. The ctr sq and IgG were as the negative control, t-test, n = 3, * p < 0.05; ** p < 0.01.
Fig 2: AD@LST enables iron reprogramming and TfR targeting to amplify the repeated PDT in GBM. (A) Schematic of the fluorescence-guided repeated PDT protocol. (B) Individual tumor growth curves, (C) tumor images, (D) mean tumor growth curves, and (E) excised tumor weights on day 14 from U87 xenograft models (n = 5). Statistical significance was assessed using two-tailed Student's t-test. (F) Histopathological and immunohistochemical analysis of tumor tissues: hematoxylin and eosin (H&E) staining, Ki-67 proliferation index (brown nuclear staining), and TUNEL apoptosis assay (green fluorescence signal). (G) Serum biochemical parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), albumin (ALB), and total protein (TP), measured on day 14. Treatment groups: G1 (Control), G2 (A@LST), G3 (AD@LS), G4 (AD@LST), G5 (A@LST + laser), G6 (AD@LS + laser), G7 (AD@LST + laser). Laser parameters: 635 nm, 200 mW/cm2, 20 min.
Fig 3: AD@LST enhances tumor cell-selective PpIX accumulation through TfR targeting and programmed iron metabolism. (A) Membrane binding of Dil-labeled AD@LST on U87 cells after 1 h at 4°C with or without excess Tf treatment. (B) Time-dependent cellular uptake of FITC-labeled AD@LST and AD@LS measured by flow cytometry (Orange: AD@LS; Red: AD@LST; Gray: Control). (C) Fluorescence images of cytosolic Fe2+ (FerroOrange) and mitochondrial Fe2+(Mito-FerroGreen) signals. Corresponding semi-quantitative analysis of (D) FerroOrange and (E) Mito-FerroGreen intensity. (F) Time-dependent PpIX fluorescence images and (G) corresponding semi-quantitative analysis. Quantification by ImageJ software. Data were normalized to the control (3 h A@LST) group (100%). (H) PpIX fluorescence images in a co-culture environment of GFP-labeled 293T and U87 cells treated with AD@LST. (I) Quantitative comparison of PpIX intensity between 293T-GFP and U87 cells. Red: PpIX, Green: 293T-GFP. Quantification by ImageJ software. Data were normalized to the 293T group (100%). (J) Western blot analysis of key heme-biosynthesis enzymes (ALAS1, CPOX, FECH). Relative protein expression was determined by normalizing band intensities to GAPDH and then to the control group (control = 1.00). Data are expressed as mean ± SD (n = 3).
Fig 4: Design and characterization of TfR-targeting and GSH-responsive liposome AD@LST. (A) TfR expression in GBM compared with adjacent normal brain tissue. (B) TfR expression across different GBM grades. (C) TCGA-GBMLGG overall survival analysis of patients stratified by TfR expression. (D) Western blot analysis of TfR in glioma cell lines (U87, U251) and non-neoplastic human embryonic kidney (293T) cells. Relative protein levels were determined by normalizing band intensities to GAPDH and then to the 293T group (293T group = 1.00). (E) Representative immunohistochemical staining for TfR in low-grade and high-grade GBM patient specimens, sourced from the Human Protein Atlas (HPA). (F) Correlation analysis between TfR and FECH expression in the TCGA dataset. (G) TEM image, (H) hydrodynamic size distribution, (I) zeta potential and (J) colloidal stability of AD@LST. GSH-responsive (10 mM) release profiles of (K) 5-ALA and (L) DFO from AD@LST. Data are presented as mean ± SD; n = 3.
Fig 5: Schematic illustration of AD@LST for tumor-targeted PpIX biosynthesis and augmented PDT through iron metabolism modulation. (A) Schematic of the targeted delivery strategy of AD@LST to TfR-overexpressing tumor cells. (B) Iron metabolism regulatory mechanism of AD@LST for enhancing mitochondrial PpIX accumulation while reducing heme biosynthesis and its downstream antioxidant metabolites. TfR: Transferrin Receptor; 5-ALA: 5-Aminolevulinic Acid; DFO: Deferoxamine; GSH: Glutathione; PpIX: Protoporphyrin IX; DCM: Dichloromethane; ETC: Electron Transport Chain; HO-1: Heme Oxygenase-1; CO: Carbon Monoxide; COPRO III: Coproporphyrin III; CPOX: Coproporphyrinogen Oxidase; FECH: Ferrochelatase.
Supplier Page from Abcam for Anti-Transferrin Receptor antibody [EPR4012]